Boston Scientific (BSX) Tops Q2 EPS by 4 cents; raises EPS guidance

Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.53, $0.04 better than the analyst estimate of $0.49. Revenue for the quarter came in at $3.6 billion versus the consensus estimate of $3.5 billion.

GUIDANCE:

Boston Scientific sees Q3 2023 EPS of $0.46-$0.48, versus the consensus of $0.48.

Boston Scientific sees FY2023 EPS of $1.96-$2.00, versus the consensus of $1.95.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
• HP Inc. projects mid-single-digit PC market decline in 2027